Impact of early postoperative hydrocortisone administration in cardiac surgical patients after cardiopulmonary bypass

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 189-194

  Ensor, Christopher R ^a,b,c   Sabo, Roy T ^d   Voils, Stacy A ^e,f,g,h  

^a Cardiothoracic Transplantation and Mechanical Circulatory Support   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Division of Neurosurgery   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g Department of Pharmacotherapy and Outcomes Science ^*  (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Atrial fibrillation; Cardiac surgery; Cardiopulmonary bypass; Hydrocortisone; Vasoactive medication

Indexed keywords

HYDROCORTISONE; VASOACTIVE AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURGICAL PATIENT; TERTIARY HEALTH CARE; ADVERSE EFFECTS; AGED; ATRIAL FIBRILLATION; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79951931334     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P468     Document Type: Article

References (27)

1. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothor Vasc Anesth 1997;11:355-66. (Pubitemid 27214906)
2. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardio Surg 2002;21:232-44. (Pubitemid 34135370)
3. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The American College of Chest Physicians/Society of Critical Care Medicine consensus conference committee. Chest 1992;101:1644-55.
4. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57. (Pubitemid 14209268)
5. Kristof AS, Magder S. Low systemic vascular resistance state in patients undergoing cardiopulmonary bypass. Crit Care Med 1999;27:1121-7. (Pubitemid 29314322)
6. Chenoweth DE, Cooper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass: evidence of generation of C3a and C5a anaphylactoxins. N Engl J Med 1981;304:497-503. (Pubitemid 11056494)
7. Westaby S. Organ dysfunction after cardiopulmonary bypass: a systemic inflammatory reaction initiated by the extracorporeal circuit. Int Care Med 1987;13:89-95. (Pubitemid 17018603)
8. Weis F, Beiras-Fernandez A, Schelling G, et al. Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin- 6 to interleukin-10 ratio and early outcome. Crit Care Med 2009;37:1685-90.
9. Leite EG, Ronald A, Rodrigues AJ, et al. Is methylene blue of benefit in treating adult patients who develop catecholamine resistant vasoplegic syndrome during cardiac surgery. Int Cardiovasc Thorac Surg 2006;5:774-8. (Pubitemid 44901245)
10. Hall RI, Stafford SM, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997;85:766-82. (Pubitemid 27418878)
11. Kilger E, Weis F, Briegel J, et al. Stress dose of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003;31:1068-74. (Pubitemid 36444415)
12. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludricortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
13. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
14. Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event. Ann Surg 1997;226:501-13. (Pubitemid 28049672)
15. Halonen J, Halonen P, Jarvinin O, et al. Glucocorticoids for the prevention of atrial fibrillation after cardiac surgery. JAMA 2007;297:1562-7. (Pubitemid 46588369)
16. Bruins P, te Velthuis H, Yazdanbakhsh AP et al. Activation of the complement system during and after cardiopulmonary bypass surgery: post-surgery activation involved C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-8.
17. Lamm G, Auer J, Weber T, et al. Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth 2006;20:51-6. (Pubitemid 43182777)
18. Eklund AM, Lyytikainen O, Klemets P, et al. Mediastinitis after more than 10 000 cardiac surgical procedures. Ann Thor Surg 2006;82:1784-9. (Pubitemid 44584908)
19. Bovill E, Terrin ML, Stump D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med 1991;115:256-65.
20. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87. (Pubitemid 351397087)
21. Whitlock RP, Rubens FD, Young E, Teoh KH. Pro: steroids should be used for cardiopulmonary bypass. J Thorac Cardiothorac Vasc Anes 2005;19:250-4.
22. Sulzer CF, Mackensen GB, Grocott HP. Con: methylprednisolone is not indicated for patients during cardiopulmonary bypass. J Thorac Cardiothorac Vasc Anes 2005;19:255-8.
23. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-73. (Pubitemid 33151027)
24. Whitlock RP, Chan S, Devereaux PJ, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary byass: a meta-analysis of randomized trials. Eur Heart J 2008;29:2592-600.
25. Ho KM, Tan JA. Benefits and risks of glucocorticoid prophylaxis in adult cardiac surgery. Circulation 2009;119:1853-66.
26. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
27. Finfer S, Chittock DR, Yu-Shuo Su S, et al., for the NICE-SUGAR study investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.